Cancer Virology Program

翻译后摘要：癌症病毒学（CV） 病毒是大约15%的人类癌症的原因。虽然取得了重大进展， 在过去的几十年里，没有针对许多癌症病毒的疫苗或特异性靶向治疗。 及其相关的恶性肿瘤。癌症病毒学（CV）项目的使命与 希尔曼癌症中心（HCC）的目标是通过获得新的 病毒感染的知识。CV成员将通过识别靶向的新癌症途径来实现这一目标 通过癌症病毒（目标1）;确定病毒性癌症的新治疗靶点/药物，并开发新的 基于病毒的抗癌疗法（目标2）;鉴定病毒性癌症的新生物标志物（目标3）;以及 发现新的致癌病毒（目标4）。为了促进这些具体目标的执行，CV已 制定了切实的目标，即建立一个富有成效、高度协作的调查小组， 致力于这些目标，在癌症病毒学领域为HCC提供独特的智力资源，并建立 这是一个特殊的研究项目，有几代科学家研究癌症病毒。作为 HCC的整体计划，CV利用了卓越的学术环境和丰富的资源， HCC。CV通过为使用癌症的基础癌症研究提供肥沃的土壤来实现这些目标 病毒和病毒性癌症作为模型系统，积极招募癌症病毒学研究人员，支持 内部和外部的互动和协作，为程序研讨会，为内部和外部 研讨会和务虚会以及癌症病毒学的试点项目研究，促进流域研究 区域，并指导初级调查员和受训人员。在高守江的领导下， 博士，简历有27名成员代表9个部门和匹兹堡大学内的3所学校。CV 成员进行以癌症为重点的研究，每年获得810万美元的直接资助，其中290万美元 是NCI资金，500万美元是其他同行评审，20万美元是非同行评审。从2015年至2019年8月，简历 成员出版了428份与癌症有关的出版物，其中9%是方案内出版，19%是方案间出版， 65%的机构间合作。CV是国际公认的领先枢纽， 新的人类癌症病毒的发现和特征。高的研究生产力 计划成员在当前的资金周期反映了CV在满足这些目标，这将是成功的 在下一个供资周期实现并扩大。

Abstract: Cancer Virology (CV) Viruses are the cause of approximately 15% of human cancers. While significant advancements have been made in the last few decades, there is no vaccine or specific targeted therapy for numerous cancer viruses and their associated malignancies. The mission of the Cancer Virology (CV) Program, which is closely aligned with that of Hillman Cancer Center (HCC), is to prevent and cure viral and nonviral cancer by acquiring new knowledge of viral infection. CV members will achieve this goal by identifying new cancer pathways targeted by cancer viruses (Aim 1); identifying novel therapeutic targets/agents for viral cancer and developing new anticancer virus-based therapeutics (Aim 2); identifying novel biomarkers for viral cancers (Aim 3); and discovering new cancer-causing viruses (Aim 4). To facilitate the execution of these specific aims, CV has developed tangible goals, which are to establish a productive, highly collaborative group of investigators devoted to these aims, provide unique intellectual resources to HCC in the area of cancer virology, and build an exceptional research program with multiple generations of scientists studying cancer viruses. As an integral program of HCC, CV takes advantage of the exceptional academic environment and rich resources of HCC. CV achieves these goals by providing fertile ground for fundamental cancer research using cancer viruses and viral cancers as model systems, active recruitment of investigators in cancer virology, support for internal and external interactions and collaborations, for program symposiums, for internal and external seminars and retreats and for pilot project research in cancer virology, stimulation of research in the catchment area, and for mentoring of junior investigators and trainees. Under the leadership of Shou-Jiang (SJ) Gao, PhD, CV has 27 members representing 9 departments and 3 schools within the University of Pittsburgh. CV members conduct cancer-focused research supported by $8.1M in total annual direct funding of which $2.9M is NCI funding, $5.0M is other peer-reviewed and $0.2M is non-peer-reviewed. From 2015-August 2019, CV members published 428 cancer-related publications representing 9% intra-programmatic, 19% inter- programmatic, and 65% inter-institutional collaborations. CV is internationally recognized as a leading hub for the discovery and characterization of new human cancer viruses. The high research productivity of the program members in the current funding cycle reflects the success of CV in meeting these goals, which will be realized and augmented in the next funding cycle.